285
Views
1
CrossRef citations to date
0
Altmetric
Vitamin D Supplementation in Patients at Risk for Fractures and Falls

Is vitamin-D supplementation not useful in patients at risk of fractures and falls?

, , , , , , , , & show all
Pages 93-95 | Received 21 Jun 2019, Accepted 04 Jul 2019, Published online: 07 Aug 2019
 

Abstract

To evaluate numerous publications that question the bone and extraosseous benefits of vitamin D diet supplementation based on results, which often transcend to public opinion, but are not well interpreted. This may have negative consequences on compliance of patients under vitamin D supplementation. Critical appraisal of several articles on vitamin D supplementation and its relationship with fractures, falls, cardiovascular diseases, and cancer incidence. Such publications have certain limitations (i.e. patients excluded because of a diagnosis of osteoporosis, or at a higher risk for fractures and falls, or because they have a vitamin D deficiency, etc.), and conclusions and/or subsequent recommendations should be approached with caution. Our research shows that patients with osteoporosis, vitamin D deficiency, and at high risk of fractures and falls should not discontinue vitamin D supplementation (often associated with calcium). It is becoming increasingly evident that patients with hypovitaminosis D are those that gain a maximal benefit from vitamin D supplementation.

摘要

评估众多基于结果质疑维生素D饮食补充剂的骨骼和骨外益处的出版物, 这些结果往往超越了公众舆论, 但没有得到很好的解读。这可能会对服用维生素D的患者的依从性产生负面影响。对几篇关于维生素D补充剂及其与骨折、跌倒、心血管疾病和癌症发病率的关系的文章进行批判性评价。这类出版物有一定的局限性(即, 由于诊断为骨质疏松症、骨折和跌倒的风险较高、或因为缺乏维生素D等原因而被排除在外的患者), 结论和/或后续建议应谨慎对待。我们的研究表明, 患有骨质疏松症、维生素D缺乏、骨折和跌倒风险较高的患者不应停止补充维生素D(通常与钙有关)。越来越明显的是, 维生素D缺乏症患者是那些从补充维生素D中获得最大好处的人。

Disclosure statement

Dr. Javier Aguilar reports grants and personal fees as speaker, member of advisory boards, and/or consultant with FAES, Gebro, Amgen, and Lilly.

Dr. Esteban Jodar reports grants and personal fees as consultant and/or speaker from Amgen, AstraZeneca, Boehringer Ingelheim, FAES, Fresenius, Janssen, Lilly, MSD, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire, and UCB.

Dr Rafael Sánchez-Borrego had a financial relationship (lecturer, member of advisory boards, and/or consultant) with 100% Natural, SEID, Shionogi, FAES, Lacer, and AC Mylan.

Dr. Julian Segura had a financial relationship (lecturer, member of advisory boards, and/or consultant) with AstraZeneca, Medtronic, and Pfizer.

Dra. Fátima Brañas has received honoraria for advisory board membership from FAES Pharma.

Dr. Yago González-Lama has received honoraria for advisory board membership from FAES Pharma.

Dr. Jorge Malouf had a financial relationship (lecturer, member of advisory boards, and/or consultant) with Gruenenthal, Esteve, AMGEN, and Lilly.

Dr. Carlos Gómez has received grants and personal fees as consultant and/or speaker from Amgen, Kiowa-Kirin, Italfármaco, FAES, Lilly, UCB, and Gebro.

Dr. Jorge Alonso has no conflict of interest.

Dr. Carmen Valdés has no conflict of interest.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.